Telling Work About Your GLP-1

Nobody's business, discussed anyway

There is a particular kind of silence that follows a colleague saying "you look amazing — what have you been doing?" in an open-plan office at 9.40 on a Tuesday.

It is not a hostile question. That is what makes it awkward. The person asking is being warm, in front of four other people, about a prescription you have not decided how you feel about yet, and there is no version of "thanks" that closes the subject.

Work is the room where this lands differently from anywhere else. You cannot leave it. The people making the assessment control things — shifts, projects, references. And in a growing number of cases the medication is arriving through the employer, which means your benefits department already knows something your team does not.

Before it is a social question, it is a benefits question

Start with the money, because for most women it decides everything downstream.

In KFF's 2024 employer survey, published in Health Affairs, 18% of large firms offering health benefits covered GLP-1 medications for weight loss — rising to 28% among firms with 5,000 or more employees¹. So coverage is real, it is growing, and it is still the minority position. Whether your employer covers this is close to arbitrary from where you sit, and it is worth a great deal of money either way.

Among people who do have it, it appears to be load-bearing. The PERCEPTIONS survey, an observational study of 518 full-time US employees starting tirzepatide for obesity or overweight — mean age 46, mean BMI 38.4 — asked exactly this. Of the 80.9% with employer-provided health insurance, 55.9% reported that it covered obesity medications. Across the whole sample, 96.5% thought employer insurance should include that coverage. And 52.3% said they would consider changing jobs in order to get that coverage².

Half the sample would move employer for a drug benefit. That is not a wellness-programme statistic; it is a retention statistic.

One caveat you should carry into that number: the study was designed and authored by employees of Eli Lilly, which makes tirzepatide. It is real survey data with a real interest behind it, and both halves of that sentence matter.

The same survey measured what the untreated condition was already costing at work. Respondents reported mean overall work impairment of 32.4% and activity impairment of 43.0%, driven mostly by presenteeism — being at the desk and not functioning, rather than being absent². Nobody was calling that a medical issue before there was a medication to attach it to.

The penalty has been measured, and it includes competence

The reason disclosure feels risky at work specifically is that the judgement is not only moral. It is about whether you are any good.

That has now been tested properly. Across four pre-registered studies in Belgium, the US and the UK, 1,205 participants read about two people with identical weight-loss outcomes: both changed diet and exercise; one also used anti-obesity medication which made him feel less hungry. Participants rated the medication user as less moral, and the effect was enormous — in the first of the four studies, a standardised difference of 1.25, which in this literature is not a nudge but a chasm³.

Then the part that belongs to work. The same participants rated the medication user lower on competence (d = 0.89) and on deservingness (d = 0.96)³. Nothing in the scenario said anything about his job. The effort discount simply spread.

Two honest caveats. The people being judged in that vignette were men, named Peter and Tom — so this is a clean measurement of the mechanism, not a measurement of what happens to a woman in your team. And it measures strangers' snap judgements, not colleagues who have worked beside you for six years.

The workplace-specific version is less settled. Karyn Dossinger, who teaches management at Loyola University Chicago's Quinlan School of Business, told the Irish Times in December 2025 that it cuts both ways: "Perhaps the employee is perceived positively because they are taking a proactive approach. Or, perceptions of them could be negative if taking a weight-loss drug is perceived as ... a shortcut or seen as having a lack of discipline [or] willpower."⁴

Which is to say: it depends on the room, and you already know your room better than any study does.

What women at work were carrying before any of this

None of this arrives on neutral ground, and the pre-existing tilt is documented.

In a nationally representative US sample of 2,290 adults, self-reported weight or height discrimination ran at 5% among men and 10% among women. Among adults with a BMI of 35 and above it reached 40%. Most pointedly, women with a BMI between 30 and 35 were three times more likely to report weight or height discrimination than male peers at a similar weight⁵.

A body size that costs a man very little costs a woman a great deal. That is the baseline the disclosure question sits on top of.

Group interviews with 420 women with a BMI above 30, aged 21 to 72, attending a hospital obesity clinic in Poland found 5.3% had experienced employment discrimination outright and 10.5% had been subject to verbal or social abuse at work⁶. The authors noted that the most common consequences the women described were emotional problems, loss of motivation, and eating more under stress — a loop in which the workplace treatment feeds the thing being punished.

What the law does and does not do

Very little, is the short answer, and it surprises people.

Weight is not a protected characteristic under US federal employment law. As of 2020 there was exactly one state with an anti-weight-discrimination statute — Michigan, which added weight to its civil rights act in 1976 — and Massachusetts and several cities had been working towards it for years without getting there⁷. Michigan is still the only one.

The most significant recent change is municipal. New York City amended its Human Rights Law to add height and weight as protected categories, and since 22 November 2023 it has been unlawful for New York City employers to discriminate against applicants and employees on those grounds, with parallel protections in housing and public accommodations⁸.

If you are not in Michigan or New York City, the protection you are relying on is not weight-based. It is whatever protects medical information generally, and the practical implication is the same either way: the less that circulates, the less there is to manage.

The appointments, which are the boring hard part

The disclosure question is the one people rehearse. The logistics are the one that actually bites.

• The escalation cadence is roughly monthly at the start. Dose steps are taken at least four weeks apart, which usually means a check-in and sometimes bloodwork. A recurring mid-morning slot is easier to hold than a series of one-off favours.
• A prescription is a prescription. Whatever your workplace does for a colleague managing blood pressure or thyroid medication, it does for this. Framing it as an ongoing prescription rather than as an event is both accurate and less interesting to everyone.
• The first eight weeks are the ones to protect. If side effects are going to make a day unworkable, that is when. Front-load the flexibility rather than spending it later.
• Watch what shifts with the money. What it costs as the dose climbs is a live number, and a coverage change at open enrolment is a household decision on a corporate timetable.

A script, and what it is for

The point of a prepared sentence is not secrecy. It is not having to decide, in the corridor, how much you owe someone.

"I've made some changes with my doctor and I'm happy with how it's going." True, complete, closed.

If you want to be open, be open — half the value of a colleague saying it out loud is that it makes it survivable for the next person, and there is a plausible case that visible normality is the only thing that shifts the competence penalty at all. But choose it as a choice. The version that goes badly is almost always the one where you improvised under a fluorescent light because someone was nice to you at the wrong moment.

Where this leaves it

The strange thing about telling work is that the employer often knows first and the colleagues find out last, and the two conversations feel nothing alike.

One is a formulary decision made by people who will never meet you, and which — on the numbers — half of employees would change jobs over. The other is a person at the next desk being friendly in a way you cannot answer in one sentence.

The evidence says the second one carries a measurable cost, that it lands harder on women than on men, and that almost nowhere in the country is there a law that cares. Which is an argument for deciding your line in advance, on a quiet evening, rather than at 9.40 on a Tuesday.

For the same problem in a room you can leave, what a GLP-1 does to your friendships.